Skip to main content
PMC home page
Heart logoLink to Heart
. 2000 Sep;84(Suppl 1):i42–i45. doi: 10.1136/heart.84.suppl_1.i42

AT1 receptor antagonists—beyond blood pressure control: possible place in heart failure treatment

J McMurray
PMCID: PMC1766530  PMID: 10956322

Full Text

The Full Text of this article is available as a PDF (127.2 KB).

Figure 1  .

Figure 1  

Open in a new tab

Mean change from baseline to last value in total exercise time (bicycle ergometry) among patients with CHF treated with placebo or candesartan cilexetil 4-16 mg for ⩽ 12 weeks (intention to treat population, n = 807).

Figure 2  .

Figure 2  

Open in a new tab

Mortality results from ELITE-I and RESOLVD pilot appear to be contradictory.

Figure 3  .

Figure 3  

Open in a new tab

Effect of combination treatment with an ACE inhibitor plus losartan on exercise tolerance and NYHA functional class.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cohn J. N., Johnson G., Ziesche S., Cobb F., Francis G., Tristani F., Smith R., Dunkman W. B., Loeb H., Wong M. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991 Aug 1;325(5):303–310. doi: 10.1056/NEJM199108013250502. [DOI] [PubMed] [Google Scholar]
  2. Cohn J. N., Tognoni G., Glazer R. D., Spormann D., Hester A. Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail. 1999 Jun;5(2):155–160. doi: 10.1016/s1071-9164(99)90038-6. [DOI] [PubMed] [Google Scholar]
  3. Dickstein K., Kjekshus J. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am J Cardiol. 1999 Feb 15;83(4):477–481. doi: 10.1016/s0002-9149(98)00898-4. [DOI] [PubMed] [Google Scholar]
  4. Granger C. B., Ertl G., Kuch J., Maggioni A. P., McMurray J., Rouleau J. L., Stevenson L. W., Swedberg K., Young J., Yusuf S. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J. 2000 Apr;139(4):609–617. doi: 10.1016/s0002-8703(00)90037-1. [DOI] [PubMed] [Google Scholar]
  5. Hamroff G., Katz S. D., Mancini D., Blaufarb I., Bijou R., Patel R., Jondeau G., Olivari M. T., Thomas S., Le Jemtel T. H. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation. 1999 Mar 2;99(8):990–992. doi: 10.1161/01.cir.99.8.990. [DOI] [PubMed] [Google Scholar]
  6. McKelvie R. S., Yusuf S., Pericak D., Avezum A., Burns R. J., Probstfield J., Tsuyuki R. T., White M., Rouleau J., Latini R. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999 Sep 7;100(10):1056–1064. doi: 10.1161/01.cir.100.10.1056. [DOI] [PubMed] [Google Scholar]
  7. Pfeffer M. A., Braunwald E., Moyé L. A., Basta L., Brown E. J., Jr, Cuddy T. E., Davis B. R., Geltman E. M., Goldman S., Flaker G. C. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327(10):669–677. doi: 10.1056/NEJM199209033271001. [DOI] [PubMed] [Google Scholar]
  8. Pitt B., Poole-Wilson P. A., Segal R., Martinez F. A., Dickstein K., Camm A. J., Konstam M. A., Riegger G., Klinger G. H., Neaton J. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000 May 6;355(9215):1582–1587. doi: 10.1016/s0140-6736(00)02213-3. [DOI] [PubMed] [Google Scholar]
  9. Pitt B., Segal R., Martinez F. A., Meurers G., Cowley A. J., Thomas I., Deedwania P. C., Ney D. E., Snavely D. B., Chang P. I. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) Lancet. 1997 Mar 15;349(9054):747–752. doi: 10.1016/s0140-6736(97)01187-2. [DOI] [PubMed] [Google Scholar]
  10. Pitt B., Zannad F., Remme W. J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 Sep 2;341(10):709–717. doi: 10.1056/NEJM199909023411001. [DOI] [PubMed] [Google Scholar]
  11. Riegger G. A., Bouzo H., Petr P., Münz J., Spacek R., Pethig H., von Behren V., George M., Arens H. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators. Circulation. 1999 Nov 30;100(22):2224–2230. doi: 10.1161/01.cir.100.22.2224. [DOI] [PubMed] [Google Scholar]
  12. Swedberg K., Pfeffer M., Granger C., Held P., McMurray J., Ohlin G., Olofsson B., Ostergren J., Yusuf S. Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. J Card Fail. 1999 Sep;5(3):276–282. doi: 10.1016/s1071-9164(99)90013-1. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES